KLP Kapitalforvaltning AS Invests $10.28 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

KLP Kapitalforvaltning AS purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 43,700 shares of the biopharmaceutical company’s stock, valued at approximately $10,283,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ALNY. Larson Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the period. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. True Wealth Design LLC raised its position in Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the last quarter. OFI Invest Asset Management acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $45,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $290.70 on Tuesday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $37.63 billion, a P/E ratio of -133.96 and a beta of 0.39. The firm has a fifty day moving average of $257.81 and a 200-day moving average of $260.02. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling

In other news, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of a number of analyst reports. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a report on Friday. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $280.00 to $328.00 in a research note on Monday. Chardan Capital reissued a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. Finally, William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $312.30.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.